| Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy W Ma, BM Gilligan, J Yuan, T Li Journal of Hematology & Oncology 9, 1-21, 2016 | 371 | 2016 |
| Cancer neoantigens as potential targets for immunotherapy W Ma, B Pham, T Li Clinical & Experimental Metastasis 39 (1), 51-60, 2022 | 41 | 2022 |
| High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer W Xiao*, W Ma*, S Wei, Q Li, R Liu, RP Carney, K Yang, J Lee, A Nyugen, ... Journal of Hematology & Oncology 12, 1-18, 2019 | 39 | 2019 |
| Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report H Li, W Ma, KY Yoneda, EH Moore, Y Zhang, LLQ Pu, GM Frampton, ... Journal of Hematology & Oncology 10 (1), 64, 2017 | 38 | 2017 |
| Increasing cure rates of solid tumors by immune checkpoint inhibitors W Ma*, R Xue*, Z Zhu*, H Farrukh, W Song, T Li, L Zheng, C Pan Experimental Hematology & Oncology 12 (1), 1-19, 2023 | 35 | 2023 |
| Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors C Zhou*, Z Yuan*, W Ma*, L Qi, A Mahavongtrakul, Y Li, H Li, J Gong, ... Journal of Hematology & Oncology 11, 1-13, 2018 | 31 | 2018 |
| Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors J Gong, JP Gregg, W Ma, K Yoneda, EH Moore, ME Daly, Y Zhang, ... Journal of the National Comprehensive Cancer Network 17 (4), 297-301, 2019 | 26 | 2019 |
| Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives LA Godoy, J Chen, W Ma, J Lally, KA Toomey, P Rajappa, R Sheridan, ... Biomarker research 11 (1), 7, 2023 | 23 | 2023 |
| Translational biomarkers and rationale strategies to overcome resistance to immune checkpoint inhibitors in solid tumors JA Chen, W Ma, J Yuan, T Li Tumor Microenvironment, 251-279, 2020 | 22 | 2020 |
| Reduced expression of Slit2 in renal cell carcinoma W Ma, Y Zhou, D Lu, D Dong, XJ Tian, J Wen, J Zhang Medical Oncology 31, 1-7, 2014 | 22 | 2014 |
| Targeting HER2 genomic alterations in non-small cell lung cancer J Zeng, W Ma, RB Young, T Li Journal of the National Cancer Center 1 (2), 58-73, 2021 | 20 | 2021 |
| Giant magnetoresistive nanosensor analysis of circulating tumor DNA epidermal growth factor receptor mutations for diagnosis and therapy response monitoring JC Nesvet, KA Antilla, DS Pancirer, AX Lozano, JS Preiss, W Ma, A Fu, ... Clinical chemistry 67 (3), 534-542, 2021 | 19 | 2021 |
| High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer Q Li*, W Ma*, S Chen, EC Tian, S Wei, RR Fan, T Wang, C Zhou, T Li Translational Lung Cancer Research 9 (4), 1361, 2020 | 15 | 2020 |
| Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC T Li, W Ma, EC Tian Chinese clinical oncology 8 (Suppl 1), S4-S4, 2019 | 10 | 2019 |
| Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer Q Li, W Ma, T Li Journal of Thoracic Disease 10 (Suppl 26), S3186, 2018 | 9 | 2018 |
| PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival O Parra*, W Ma*, Z Li, BN Coffing, K Linos, RE LeBlanc, S Momtahen, ... Journal of Cutaneous Pathology 50 (10), 903-912, 2023 | 6 | 2023 |
| Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC W Ma, J Zeng, S Chen, Y Lyu, KA Toomey, CT Phan, KY Yoneda, T Li Biomarker Research 9, 1-20, 2021 | 5 | 2021 |
| Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M … W Ma, J Gong, J Shan, D Lewis, W Xiao, EH Moore, Y Zhang, J Hung, ... JCO Precision Oncology 2, 1-7, 2018 | 5 | 2018 |
| Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry W Ma, S Wei, EC Tian, B Mclaughlin, M Jaimes, DJ Montoya, ... Frontiers in Immunology 14, 1206631, 2023 | 4 | 2023 |
| Labyrinthin expression is associated with poor prognosis in patients with non-small-cell lung cancer W Ma, J Zeng, DJ Montoya, K Toomey, C Zhou, S Chen, D Liu, M Babich, ... Cancers 15 (3), 924, 2023 | 4 | 2023 |
Jianda Yuan MD. Ph.D.Memorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
